

## Technology Advisory Interests Register

**Topic: Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]**

**Publication Date: TBC**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Elizabeth Thurgar	TAC Committee Member	Financial	I am currently working with Pfizer and Gilead in unrelated indications (NSCLC and Gastric Cancer). In the last 12 months I have worked with JNJ for multiple myeloma.	16/10/2025	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal
Mike Chambers	TAC Committee Member	Financial	I have participated in an advisory panel for Pfizer (possible comparator company) in an unrelated disease area: prostate cancer	16/10/2025	It was agreed that Mike's declaration would not prevent them from participating in discussions on this appraisal
Jonathan Sive	TAC Committee Member	Financial	I was sponsored to attend a medical conference by Johnson & Johnson (Janssen-Cilag)	17/10/2025	It was agreed that Jonathan's declaration would not prevent them from participating in discussions on this appraisal
Dr Renata Walewska	Expert	Direct - Financial	<ul style="list-style-type: none"> <li><b>Speaker engagements:</b> AbbVie, AstraZeneca, BeOne Medicines Ltd, Eli Lilly, Janssen</li> </ul>	22/07/2025	It was agreed that Renata's declaration would not prevent them from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> <li>• <b>Advisory boards:</b> AbbVie, AstraZeneca, BeOne Medicines Ltd, Janssen, Eli Lilly, SecuraBio</li> <li>• <b>Meeting sponsorship:</b> AbbVie, AstraZeneca, BeOne Medicines Ltd, Janssen, Takeda</li> <li>• <b>Educational material development:</b> BeOne Medicines Ltd, Limbic, Medscape</li> </ul>		providing expert advice to the committee